Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00808639 · ClinicalTrials.gov registry record · Phase 2
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
A Phase 2 study of Bladder Cancer and Muscle-invasive Bladder Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 4
- Study locations
NCT00808639 is a Phase 2 study of Bladder Cancer and Muscle-invasive Bladder Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 39 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT00808639, a Phase 2 study of Bladder Cancer and Muscle-invasive Bladder Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this research study is to test the effectiveness of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in combination with pegfilgrastim followed by radical surgery in patients with muscle-invasive urothelial carcinoma.
Conditions Studied
Interventions
- DRUG Doxorubicin
- DRUG Methotrexate
- DRUG cisplatin
- DRUG Pegfilgrastim
- DRUG vinblastine
Study Locations (4)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
- Lahey Clinic - Burlington
Pennsylvania
- University of Pittsburgh Cancer Institute - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2008-12 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00808639
The ClinicalTrials.gov registry entry for NCT00808639 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (100% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 5 interventions - of which Doxorubicin is the first listed.
NCT00808639 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00808639 about?
NCT00808639 is a clinical study titled "Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma". The purpose of this research study is to test the effectiveness of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in combination with pegfilgrastim followed by radical surgery in patients with muscle-invasive urothelial carcinoma.
What is the current status of trial NCT00808639?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2008-12. Estimated completion is 2016-09.
What conditions does trial NCT00808639 study?
This clinical trial studies the following conditions: Bladder Cancer, Muscle-invasive Bladder Cancer.
What interventions are being tested in trial NCT00808639?
The interventions under investigation include: Doxorubicin (DRUG), Methotrexate (DRUG), cisplatin (DRUG), Pegfilgrastim (DRUG), vinblastine (DRUG).
Who is sponsoring clinical trial NCT00808639?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00808639 being conducted?
This trial has 4 study locations across Massachusetts, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Telehealth Intervention for Ostomy Self-Management
RECRUITING · Phase 2
-
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
RECRUITING · Phase 2
-
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
RECRUITING · Phase 2
-
Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)
RECRUITING · Phase 2
-
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
RECRUITING · Phase 2
-
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.